2021 American Society of Hematology Annual Meeting*

In older/unfit patients with AML and poor-risk cytogenetics, frontline treatment with venetoclax plus azacitidine improved DoR and OS vs Aza in wild-type but not mutated TP53.

Sustained superior efficacy of asciminib vs bosutinib at Week 48 in the ASCEMBL trial among patients with CML-CP previously treated with ≥2 TKIs.

Retrospective analysis of newly diagnosed patients with AML suggests similar response rates and, in the overall patient population, longer overall survival with frontline CPX-351 compared with a hypomethylating agent plus venetoclax.

In young adults with newly diagnosed adverse-risk AML, venetoclax plus decitabine was associated with a composite CR rate of 76% and in a historical comparison showed a better efficacy and safety profile than cytarabine/idarubicin.

Preliminary results were promising in a large, population-based, risk-adapted trial using a pediatric-based regimen in patients aged 18-55 years with newly diagnosed ALL/LBL.

Initial results from this phase I/II trial suggest that the 3-drug regimen is active in heavily pretreated and prior FLT3 inhibitor–exposed patients with relapsed/refractory disease with a CRc rate of 78%.

The combination of azacitidine, venetoclax, and magrolimab demonstrated high response rates with a manageable safety profile in venetoclax-naive patients with newly diagnosed or relapsed/refractory AML.

In this analysis, comparable efficacy with better tolerance was reported for low-dose dasatinib vs standard-dose dasatinib in patients with newly diagnosed chronic-phase CML.

In patients with R/R FLT3-mutated AML, the combination of gilteritinib plus venetoclax was tolerable and efficacious, with no new safety signals.

In patients with newly diagnosed IDH1-mutated AML who were ineligible for intensive chemotherapy, addition of ivosidenib to azacitidine extended event-free survival in this randomized, placebo-controlled phase III trial.

Phase III study results show significantly higher composite complete remission rates but similar overall survival with gilteritinib + azacitidine vs azacitidine alone in patients with newly diagnosed FLT3-mutated AML ineligible for intensive induction chemotherapy.